Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes

ONS News. 2006;21(8 Suppl):21-2.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use
  • Carcinoma, Renal Cell / diagnosis
  • Carcinoma, Renal Cell / therapy*
  • Disease-Free Survival
  • Drug Delivery Systems
  • Humans
  • Indoles / therapeutic use
  • Interleukin-2 / therapeutic use
  • Karnofsky Performance Status
  • Kidney Neoplasms / diagnosis
  • Kidney Neoplasms / therapy*
  • Neoplasm Staging
  • Nephrectomy
  • Niacinamide / analogs & derivatives
  • Nurse's Role
  • Oncology Nursing / organization & administration
  • Patient Education as Topic
  • Phenylurea Compounds
  • Prognosis
  • Pyridines / therapeutic use
  • Pyrroles / therapeutic use
  • Risk Assessment
  • Safety Management
  • Sorafenib
  • Sunitinib
  • Survival Analysis

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Interleukin-2
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Sunitinib